A propósito de un caso: uso de la silimarina/silibinina como análogo molecular del remdesivir para el tratamiento de pacientes diagnosticados de COVID-19 con síndrome de dificultad respiratoria aguda leve o moderado. Reporte de caso / Purpose of a case: use of silymarin / silibinin as a molecular analogue of remdesivir for the treatment of patients diagnosed of COVID-19 with acute mild or moderate respiratory difficulty syndrome. Case report.

ABSTRACT

The respiratory disease caused by SARS-CoV2 is an infectious-contagious viral disease that affects our population, especially older adults and young adults throughout the world. One of the main causes of this pathology is the limited immunization capacity at a global level, especially in developing countries, to combat outbreaks of this disease. It develops in phases of very characteristic respiratory symptoms which can guide an early diagnosis, otherwise it may require hospitalization for treatment; At a global and local level, different therapies have been tried without complete success. Presumptive diagnosis is clinical and confirmatory through nasopharyngeal swabs, which isolate beta virus, SARS-CoV-2 coronavirus, a name issued by the World Health Organization, who declared the pandemic for this disease in particular. A case of a patient with the disease caused by the virus in question is presented who comes to our health home, for not accessing a more complex hospital unit, due to hospital saturation, with a mild to moderate respiratory syndrome, in view of the impossibility of accessing other treatments, we started the administration of silymarin/silibinin in daily doses twice a day. In order for the treatment tested with different molecules to have a common denominator, which is based on attacking the cascade of inflammatory cytokines derived from the activation of the STAT3 receptor and the modulation of type 1 IFG; with corticotherapy mainly dexamethasone, or methylprednisolone, and molecules such as Remdesivir, Sofosbuvir and Ribavirin, which continue to be the focus of discussion, so optional treatments are being evaluated to combat the effects of this disease. The incidence of this disease is global, being higher in underdeveloped countries which do not have an appropriate immunization program.